At a Glance
- Companies: Sanofi, Dren Bio
- Location: US
- Deal value: Up to $1.7 billion
- Focus area: Autoimmune disease (B-cell depletion)
- Next steps: Sanofi leads development and commercialisation; Phase I trials ongoing
What happened?
Sanofi has expanded its collaboration with US biotech Dren Bio to develop B-cell depletion therapies for autoimmune diseases in a deal worth up to $1.7 billion.
Why does it matter?
The deal strengthens Sanofi’s autoimmune pipeline and signals continued investment in novel immune therapies, particularly those targeting B cells.
Who’s behind it?
Sanofi and Dren Bio are collaborating, with Sanofi taking the lead in further development and commercialisation.
How was it achieved?
Sanofi will pay an upfront $100 million and up to $1.7 billion in milestones, with Dren Bio retaining an option for 50/50 profit-sharing in the US.
What’s next?
Phase I trials are ongoing; Sanofi will advance the programme into later-stage development and commercialisation.
What are people saying?
Sanofi’s Alyssa Johnsen said the expanded alliance reflects a commitment to best-in-class therapies for immune-mediated diseases.